23:02 , Jul 25, 2019 |  BC Extra  |  Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
01:55 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Aeglea raises $60M follow-on

Human enzyme therapeutic company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) raised $60 million through the sale of 3.8 million shares at $8 in a follow-on Feb. 6. The price is a 16% discount to Aeglea's close of...
22:41 , Jul 20, 2018 |  BC Extra  |  Company News

Management tracks: Merck KGaA, Aeglea

Merck KGaA (Xetra:MRK) hired Maria Rivas as SVP, head of global medical affairs. She was SVP, head of medical affairs at Merck & Co. Inc. (NYSE:MRK). Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said interim...
20:45 , May 30, 2018 |  BC Extra  |  Company News

Management tracks: Zafgen, Rigel

Metabolic disease company Zafgen Inc. (NASDAQ:ZFGN) hired Brian McVeigh as CBO. He was VP of worldwide business development transactions and investment management at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Immunology and cancer company Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)...
00:27 , Jul 21, 2017 |  BC Extra  |  Company News

Management tracks

Enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) said President and CEO David Lowe resigned. Director and former interim CMO Anthony Quinn will be interim CEO while the company seeks Lowe's successor. Neurology and cardiovascular company...
23:37 , Jul 17, 2017 |  BC Extra  |  Company News

Management tracks

Osteoporosis and cancer play Radius Health Inc. (NASDAQ:RDUS) named Jesper Hoiland president and CEO. He was president of the U.S. division at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Gene therapy company Freeline Therapeutics (London, U.K.) appointed...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
05:08 , Jun 16, 2017 |  BC Week In Review  |  Financial News

Aeglea prices $12.3M follow-on

On June 6, enzyme therapy company Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) raised $12.3 million through the sale of 3 million shares at $4.10 in a follow-on underwritten by JonesTrading Institutional Services. Aeglea BioTherapeutics Inc. (NASDAQ:AGLE), Austin,...